Showing posts with label pharmaceutical. Show all posts
Showing posts with label pharmaceutical. Show all posts

Wednesday, April 1, 2020

India may soon ease some drug export curbs under US pressure: Report

India will likely relax some export restrictions on pharmaceutical products soon due to intense pressure from the United States which is worried about drug shortages as the number of coronavirus cases surge, two Indian government officials told Reuters.

India, which supplies more than a quarter of the world's generic drugs, last month restricted exports of 26 pharmaceutical ingredients and the medicines made from them. The move was seen as an attempt to secure supplies for its domestic population after the outbreak played havoc with the industry's supply chain globally.

The restrictions are not complete bans but impede sales of drug and drug ingredients overseas by specifying circumstances for their export and requiring firms to procure a "no objection" certificate from the government.

An easing of those restrictions will probably come within two days and will likely include Paracetamol, a common pain reliever also known as acetaminophen, the government officials in New Delhi said.

"There is so much (U.S.) pressure on the government. For U.S. what matters is Paracetamol, it matters to them significantly," said one official, adding that India had adequate stock of the drug for domestic use for at least four months.

The restrictions will be lifted for all countries, the officials said, but it was not immediately clear exactly how many drugs formulations would be exempted.

ALSO READ: Coronavirus LIVE: India cases at 1,637; search on for Delhi mosque visitors

Both officials declined to be identified due to the sensitive nature of the discussions. India's commerce ministry did not immediately respond to a request for comment.

The U.S. government said in a statement on Tuesday that Secretary of State Mike Pompeo had spoken with India's foreign minister and sought cooperation in strengthening global pharma manufacturing and supply chains, but gave no further details.

President Donald Trump has warned Americans of a "painful" two weeks ahead in fighting the virus. Nearly 3,900 people have died in the United States, and the total confirmed U.S. cases has risen to 187,000.

Imports from India accounted for 24% of medicines and 31% of medicine ingredients to the United States in 2018, according to the U.S. Food and Drug Administration.

ALSO READ: Covid-19: Apparel exporters seeks stimulus package covering wages, credit

India was, however, unlikely to ease a ban on the export of malaria drug hydroxychloroquine, which came in addition to the restrictions on the 26 drugs and formulations. The drug is being tested to see if it is effective in treating patients with COVID-19.

The United States' Health and Human Services has listed hydroxychloroquine as a medical resource that was subject to hoarding prevention measures.

Monday, March 9, 2020

'Drugs imported from unregistered dealers cannot be sold to local buyers'

Q. We are pharmaceutical manufacturers. We had imported raw material under the advance authorisation scheme to export the final product to USA. Due to business/trade circumstances the order was cancelled and the raw material is in our factory. How can we dispose it of? There are local buyers who intend to purchase it from us, as it is still saleable and has sufficient expiry date. Please advise us, referring to the relevant section/circular.

Since the export obligation is not fulfilled, you have to regularise in accordance with Para 4.49 of the HBP, which, besides other conditions, involves payment of duty on the raw materials with interest. Thereafter, you can transfer the raw material, other than drugs imported from unregistered sources, to local buyers. Do take special note of sub-para (g) of Para 4.49 that requires you to destroy or re-export drugs imported from unregistered sources with pre-import condition.

Q. This refers to the query regarding DGFT PN 55 dated January 3, 2020 (Chatroom, February 25, 2020), allowing extension in the EO period. The final EO period has been extended, and shipments have been made during this period — i.e., from expiry date of EPCG authorisation to date when request for extension was made. Will shipments made during this period go towards discharge of EO, or is that a matter for the Policy Relaxation Committee (PRC)?

In my opinion, the shipments made within the original or extended EO period can be counted towards discharge of EO, regardless of when you made the application for EO extension.

Q. We obtained advance authorisation for items covered under Appendix 4J of HBP. We did not fulfil the export obligation within the initial EO period of six months, or even within the extended EO period of nine months. The import item was removed from Appendix 4J, 18 months after issuance of advance authorisation. Thereafter, we fulfilled the EO within 24 months. Given this, is there any remedy for regularising and redeeming the authorisation? If the answer is yes, what is the quantum of composition fee for extension?

I do not think removal of the item from Appendix 4J after the expiry of the initial and extended EO periods of your advance authorisation will help you. However, you may try your luck with the PRC.

Q. We want to import some machinery from a foreign party on a temporary lease and, after using it for some time, send it back to the same party. What are the duty implications?

You can import the machinery under the exemption notification 72/2017-Cus dated August 10, 2017. Alternatively, you can import it on payment of full duty, and after use, re-export it under claim of duty drawback under Section 74 of the Customs Act, 1962, read with notification 19/1965-Cus dated February 6, 1965.

Monday, January 27, 2020

Pharma shares gain; Dr Reddy's, Alembic, Divis, Laurus Labs hit 52-wk highs


Shares of pharmaceutical companies were in focus on Monday, in an otherwise weak market, on the back of a slew positive corporate announcements. Dr Reddy’s Laboratories, Alembic Pharmaceuticals, Divis Laboratories and Laurus Labs were trading at their respective 52-week highs at the bourses on Monday.

At 12:06 pm, the S&P BSE Healthcare index was the top gainer among sectoral indices, and was up 1.1 per cent. In comparison, the benchmark S&P BSE Sensex was trading 0.43 per cent lower. The healthcare index was trading at its highest level since May 3, 2019.

Wockhardt, Strides Pharma Science, Alembic Pharmaceuticals, Pfizer and IOL Chemicals & Pharmaceuticals were up in the range of 5 to 9 per cent in the intra-day trade today. Further, Dr Reddy’s Laboratories, GlaxoSmithKline Pharmaceuticals, Astrazencea Pharma India, Laurus Labs, Novartis India, Dr. Lal PathLabs and Sanofi India, Lincoln Pharmaceuticals and Aurobindo Pharma from the index were up between 3 and 4 per cent.

Among the individual stocks, Dr Reddy’s Laboratories moved higher by 3 per cent to Rs 3,111, bouncing back 4 per cent from its intra-day low of Rs 3,002, on the BSE after the company reported strong margins improvement in the December quarter.

The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) improved 200 basis points to 24.5 per cent in Q3FY20 from 22.5 per cent reported in the year ago quarter. The profits were impacted due to trigger based impairment charge taken on a few products including gNuvaring, the company said.

It posted a consolidated net loss of Rs 570 crore in Q3FY20, on account of Rs 1,320 crore on impairment of non-current assets. It had reported a net profit of Rs 485 crore in the previous year quarter.

Besides, Wockhardt rallied 9 per cent, to Rs 325 on the BSE, on the back of heavy volumes. The stock has surged 39 per cent thus far in the month of January as against a 0.45 per cent rise in the Sensex.

On January 16, the company announced that it has received approval from the country’s drug regulator to market Emrok IV and Emrok (oral) which would treat acute bacterial skin infections, including diabetic foot infection, caused by the super bug methicillin-resistant staphylococcus aureus (MRSA). Their launch is expected in the next few months and will be primarily used on critically-ill patients.

Furthermore, Strides Pharma Science soared 6 per cent to Rs 442 in the intra-day trade today on the back of the company announcing that its formulation facility at Alathur, Chennai underwent the US Food and Drug Administration (USFDA) inspection which concluded with “Zero 483 observations”. The facility recently completed a significant capacity expansion which will support the growth momentum for the US business, the company.

In a separate exchange filing, Strides said the USFDA has approved the company’s triamcinolone acetonide ointment, which is used to treat various skin infections.

Alembic Pharma, too, hit a 52-week high of Rs 633, up 7 per cent today. Last week, the company had said that it received the US drug regulator's approval for Bosentan tablets, 62.5 mg and 125 mg, indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1).

Saturday, December 28, 2019

Gene therapy to conquering hepatitis C: A decade of medical breakthroughs


For all the flak the pharmaceutical industry has taken for its exorbitant pricing practices, there's no getting around the fact that it's been a pretty stunning decade for medical progress.

Multiple new categories of medicines have moved from dreams and lab benches into the market and people’s lives, and investors who came along for the ride often reaped extraordinary profits. The Nasdaq Biotech Index is up 360% over the last 10 years to the S&P 500's 190%. And that’s without mentioning the hundreds of billions of dollars in takeovers that rewarded shareholders with windfalls.

As 2020 approaches, it's worth highlighting how far we've come in the past 10 years in developing new therapies and approaches to treating disease, even as politicians grapple with how to rein in health-care costs without breaking an ecosystem that incentivizes the search for new discoveries. Here are some of the decade’s biggest medical breakthroughs:

Cell therapies: First approved in the U.S. two years ago, these treatments still sound like science fiction. Drugmakers harvest immune cells from patients, engineer them to hunt tumors, grow them by the millions into a living drug, and reinfuse them. Yescarta from Gilead Siences Inc. and Novartis AG’s Kymriah — the two treatments approved so far — can put patients with deadly blood cancers into remission in some cases. At the beginning of the decade, academics were just beginning early patient tests.

It’s still early days for the technology, and some issues are holding these drugs back. There are significant side effects, and the bespoke manufacturing process is expensive and time-consuming. That has contributed to a bruising price tag: Both of the approved medicines cost over $350,000 for a single treatment. And for now, cell therapy is mostly limited to very sick patients who have exhausted all other alternatives.

Luckily, more options are on their way. Some drugmakers are focused on different types of blood cancers. Others hope to mitigate side effects or create treatments that can be grown from donor cells to reduce expenses and speed up treatment. In the longer run, companies are targeting trickier solid tumors. Scientists wouldn't be looking so far into the future without this decade’s extraordinary progress.

Gene therapies: Researchers have spent years trying to figure out how to replace faulty DNA to cure genetic diseases, potentially with as little as one treatment. Scientific slip-ups and safety issues derailed a wave of initial excitement about these therapies starting in the 1990s; the first two such treatments to be approved in Europe turned out to be commercial flops.

This decade, the technology has come of age. Luxturna, a treatment developed by Spark Therapeutics Inc. for a rare eye disease, became the first gene therapy to get U.S. approval in late 2017. Then in May came the approval of Novartis AG’s Zolgensma for a deadly muscle-wasting disease. The drugs have the potential to stave off blindness and death or significant disability with a single dose, and, unsurprisingly, Big Pharma has given them a substantial financial endorsement. Roche Holding AG paid $4.7 billion to acquire Spark this year, while Novartis spent $8.7 billion in 2018 to buy Zolgensma developer Avexis Inc.

Dozens of additional therapies are in development for a variety of other conditions and should hit the market in the next few years. They offer the tantalizing potential not just to cure diseases, but to replace years of wildly expensive alternative treatment. If drugmakers can resist the temptation to squeeze out every ounce of value by doing things like charging $2.1 million for Zolgensma, there’s potential for these treatments to save both lives and money.

RNA revolution: The above treatments modify DNA; this group uses the body’s messaging system to turn a patient’s cells into a drug factory or interrupt a harmful process. Two scientists won a Nobel Prize in 2006 for discoveries related to RNA interference (RNAi), one approach to making this type of drug, showing its potential to treat difficult diseases. That prompted an enormous amount of hype and investment, but a series of clinical failures and safety issues led large drugmakers to give up on the approach. Sticking with it into this decade paid off.

Alnylam Inc. has been working since 2002 to figure out the thorny problems plaguing this class of treatments. It brought two RNAi drugs for rare diseases to the market in the past two years and has more on the way. The technology is also moving from small markets to larger ones: Novartis just paid $9.7 billion to acquire Medicines Co. for its Alnylam-developed drug that can substantially lower cholesterol with two annual treatments.

Ionis Pharmaceuticals Inc. and Biogen Inc. collaborated on Spinraza, a so-called antisense drug that became the first effective treatment for a deadly rare disease. It was approved in late 2016 and had one of the most impressive drug launches of the decade. And Moderna Therapeutics rode a wave of promising messenger RNA-based medicines to the most lucrative biotechnology IPO of all time in 2018. From pharma abandonment to multiple approvals and blockbuster sales potential in under 10 years. Not bad!

Cancer immunotherapy: Scientists had been working on ways to unleash the human immune system on cancers well before the 2010s without much luck. Checkpoint inhibitors — drugs that release the brakes on the body's defense mechanisms — have since produced outstanding results in a variety of cancers and are the decade’s most lucrative turnaround story.

Merck got a hold of Keytruda via its 2009 acquisition of Schering-Plough, but it was far from the focus of that deal. Once Bristol-Myers Squibb & Co. produced promising results for its similar drug, Opdivo, Merck started a smart development plan that has turned Keytruda into the world’s most valuable cancer medicine. It’s now available to treat more than 10 types of the disease, and has five direct competitors in the U.S. alone. Analysts expect the category to exceed $25 billion in sales next year.

If anything, the drugs may have been too successful. Copycat efforts are pulling money that could fund more innovative research. There are thousands of trials underway attempting to extend the reach of these medicines by combining them with other drugs. Some are based more on wishful thinking than firm scientific footing. Still, the ability to shrink some previously intractable tumors is a considerable advance. If drugmakers finally figure out the right combinations and competition creates pricing pressure that boosts access, these medicines will do even more in the years to come.

Conquering hepatitis C: From a combined economic and public-health standpoint, a new group of highly effective hepatitis C medicines may outstrip just about anything else on this list so far. Cure rates for earlier treatments weren’t especially high; they took some time to work and had nasty side effects. The approval of Gilead’s Sovaldi in 2013, followed in time by successor drugs such as AbbVie Inc.’s Mavyret, have made hepatitis C pretty easily curable in a matter of weeks. For Gilead, getting to market rapidly with its drug proved enormously profitable; it raked in over $40 billion in revenue in just three years.

Hepatitis C causes liver damage over time that can lead to transplants or cancer. The existence of a rapid cure is a significant long-term boon even if the initial pricing on the drugs made them, in some cases, prohibitively expensive. Sovaldi notoriously cost $1,000 per pill at launch and over $80,000 for a course of treatment. The good new is, treatments have become a lot more affordable, which should allow this class of drugs to have a broad and lasting positive health impact.

Hepatitis C is one of the relatively few markets where the drug-pricing system has worked well. As competing medicines hit the market, the effective cost of these treatments plummeted. That, in turn, made the drugs more accessible to state Medicaid programs and prison systems, which operate on tight budgets and care for populations with higher rates of hepatitis C infection. Louisiana has pioneered the use of a “Netflix model,” under which the state paid an upfront fee for unlimited access to the drug. It’s an arrangement that will help cure thousands of patients, and other states are likely to follow its lead.

Many of the medicines highlighted in this column have list prices in the six figures, a trend that’s helped drive up America’s drug spending by more than $100 billion since 2009. Building on this decade’s medical advances is going to lead to even more effective medicines that will likely come with steeper prices. I’d like to hope that policymakers will come up with a solution that better balances the need to reward innovation with the need to keep medicines accessible. That would really be a breakthrough.

Saturday, June 1, 2019

Pharma's share in greenhouse emissions more than automotive sector: Study

Rarely does mention of the pharmaceutical industry conjure up images of smoke stacks, pollution and environmental damage.

Yet our recent study found the global pharmaceutical industry is not only a significant contributor to global warming, but it is also dirtier than the global automotive production sector.

It was a surprise to find how little attention researchers have paid to the industry’s greenhouse gas emissions. Only two other studies had some relevance: one looked at the environmental impact of the US health-care system and the other at the pollution (mostly water) discharged by drug manufacturers.

Our study was the first to assess the carbon footprint of the pharma sector.

More polluting
More than 200 companies represent the global pharmaceutical market, yet only 25 consistently reported their direct and indirect greenhouse gas emissions in the past five years. Of those, only 15 reported their emissions since 2012.

One immediate and striking result is that the pharmaceutical sector is far from green. We assessed the sector’s emissions for each one million dollars of revenue in 2015. Larger businesses will always generate more emissions than smaller ones; in order to do a fair comparison, we evaluated emissions intensity.

We found it was 48.55 tonnes of CO2e (carbon dioxide equivalent) per million dollars. That’s about 55 per cent greater than the automotive sector at 31.4 tonnes of CO2e/$M for that same year. We restricted our analysis to the direct emissions generated by the companies’ operations and to the indirect emissions generated by the electricity purchased by these companies from their respective utilities companies.

The total global emissions of the pharma sector amounts to about 52 megatonnes of CO2e in 2015, more than the 46.4 megatonnes of CO2e generated by the automotive sector in the same year. The value of the pharma market, however, is smaller than the automotive market. By our calculations, the pharma market is 28 per cent smaller yet 13 per cent more polluting than the automotive sector.

Extreme variability
We also found emissions intensity varied greatly within the pharmaceutical sector. For example, the emissions intensity of Eli Lilly (77.3 tonnes of CO2e/$M) was 5.5 times greater than Roche (14 tonnes CO2e/$M) in 2015, and Procter & Gamble’s CO2 emissions were five times greater than Johnson & Johnson even though the two companies generated the same level of revenues and sell similar lines of products.

Energy use, including heating, ventilation and air conditioning, in the manufacturing facilities of pharmaceutical companies produces large amounts of greenhouse gas emissions. (Shutterstock)
We found outliers too. The German company Bayer AG reported emissions of 9.7 megatonnes of CO2e and revenues of US$51.4 billion, yielding an emission intensity of 189 tonnes CO2e/$M. This intensity level is more than four times greater than the overall pharmaceutical sector.

In trying to explain this incredibly large deviation, we found that Bayer’s revenues derive from pharmaceutical products, medical equipment and agricultural commodities. While Bayer reports its financial revenues separately for each division, it lumps together the emissions from all the divisions.

The company also reports and tracks its emission intensity in terms of tonnes of CO2e produced for each tonne of manufactured goods, whether fertilizer or Aspirin, for example.

This level of opacity makes it not only impossible to assess the true environmental performance of these kind of companies. It also raises questions about the sincerity of these companies’ strategies and actions in reducing their contribution to climate change.

We also estimated how much the pharmaceutical sector would have to reduce its emissions to comply with the reduction targets in the Paris Agreement.

We found that by 2025, the overall pharma sector would need to reduce its emissions intensity by about 59 per cent from 2015 levels. While this is clearly a far cry from their current levels, it is interesting to note that some of the 15 largest companies are already operating at that level, namely Amgen Inc., Johnson & Johnson and Roche Holding AG.

If those performance levels are achievable by some, why can’t they be achieved by all?

Three of the most profitable pharmaceutical companies have some of the lowest greenhouse gas emissions. (Shutterstock)
These three leading companies are also the ones with the highest level of profitability and revenue growth in the whole sector. Indeed Roche, Johnson & Johnson and Amgen showed revenue increases of 27.2 per cent, 25.7 per cent and 7.8 per cent respectively between 2012 and 2015, while managing to reduce their emissions by 18.7 per cent, 8.3 per cent and eight per cent respectively. This supports the premise that environmental and financial performance aren’t mutually exclusive.

The pharmaceutical industry is responsible for some serious environmental impacts beyond greenhouse gas emissions. For example, the waste water from drug manufacturers in Patancheru, India has left river sediment, ground water and drinking water polluted. Researchers estimated that in a single day, 44 kilograms of ciprofloxacin, a broad-spectrum antibiotic, was released — enough to treat everyone in a city of 44,000 inhabitants.

Clearly, there is a dire need for more extensive and sustained research as well as more scrutiny of the pharmaceutical industry’s environmental practices and performance. Healing people is no justification for killing the planet.
The Conversation
Lotfi Belkhir, Associate Professor & Chair of Eco-Entrepreneurship, McMaster University